• Zevra Therapeutics reported first-quarter 2026 results showing sales of US$36.22 million and net income of US$37.89 million, a shift from a net loss a year earlier.
• The strong profit print was partly driven by unusual items and comes amid recent shareholder dilution, prompting closer scrutiny of the earnings quality.
• We’ll now explore how the earnings jump, aided by unusual items, affects Zevra Therapeutics’ existing investment narrative in rare disease therapies.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Zevra Therapeutics Investment Narrative Recap

To own Zevra Therapeutics, you really have to believe its rare disease focus can translate into durable, high quality earnings from a small but defendable set of therapies. The Q1 2026 profit spike, helped by unusual items and coming after fresh dilution, matters mainly to how you view earnings quality in the near term; the biggest current risk remains whether ultra-orphan products like MIPLYFFA can support consistent, cash backed profitability.

The most relevant recent update alongside Q1 results is Zevra’s plan to present at the H.C. Wainwright BioConnect Investor Conference on May 19, 2026. Strong headline earnings and the US$50.0 million SDX portfolio sale give management a timely backdrop to clarify how much of the current profit run rate is repeatable and how it funds MIPLYFFA, OLPRUVA and the pipeline without leaning too heavily on further equity issuance.

Yet behind the impressive profit print, investors should be aware that weak free cash flow and past OLPRUVA write downs could still...

Zevra Therapeutics' narrative projects $296.5 million revenue and $151.4 million earnings by 2028.

Uncover how Zevra Therapeutics' forecasts yield a $23.22 fair value, a 111% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming revenue of about US$256.4 million and earnings of roughly US$117.7 million by 2028, so if you worry about slow rare disease adoption and high costs, Q1’s unusual item boosted profit might either soften or reinforce that pessimism depending on how you interpret it.

Explore 10 other fair value estimates on Zevra Therapeutics - why the stock might be worth over 6x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Zevra Therapeutics research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Zevra Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zevra Therapeutics' overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• Find 50 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.